Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01646177 · ClinicalTrials.gov registry record · Phase 3
A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,346
- Enrollment target
NCT01646177: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT01646177 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,346 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (74% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01646177, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,346 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.
Primary Outcome
The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0,1) response was defined as a post-baseline sPGA score of 0 or 1.
Interventions
- DRUG Placebo
- DRUG 50 mg etanercept
- DRUG 80 mg ixekizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,346 participants |
| Start Date | 2012-07-28 |
| Est. Completion | 2019-07-22 |
| Phase | Phase 3 |
What the finished NCT01646177 record still lists
NCT01646177 is an interventional study that assigns participants to a tested intervention. Its 1,346 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (74% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01646177 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01646177 about?
NCT01646177 is a clinical study titled "A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)". This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.
What is the current status of trial NCT01646177?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,346 participants. The study started on 2012-07-28. Estimated completion is 2019-07-22.
What interventions are being tested in trial NCT01646177?
The interventions under investigation include: Placebo (DRUG), 50 mg etanercept (DRUG), 80 mg ixekizumab (DRUG).
Who is sponsoring clinical trial NCT01646177?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01646177's enrollment target sits among peer trials
1,346 182nd of 2000 higher than 1,819 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06731608 · 1,344 participants · NA
OsteoPorotic fracTure preventION System (OPTIONS) Research Study
- NCT06318169 · 1,350 participants · Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- NCT06605404 · 1,350 participants
Pan-tumor MRD Study
- NCT06806163 · 1,350 participants · NA
Machine-Learning Prediction and Reducing Overdoses With EHR Nudges
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI